Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 59, Issue 16, Pages 7598-7616Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.6b00698
Keywords
-
Categories
Funding
- European Union [603240]
- European Community [283570]
- Klaus Tschira Foundation
- Alexander von Humboldt Foundation at HITS
Ask authors/readers for more resources
Flavonoids represent a potential source of new antitrypanosomatidic leads. Starting from a library of natural products, we combined target-based screening on pteridine reductase 1 with phenotypic screening on Trypanosoma brucei for hit identification. Flavonols were identified as hits, and a library of 16 derivatives was synthesized. Twelve compounds showed EC50 values against T. brucei below 10 mu M. Four X-ray crystal structures and docking studies explained the observed structure activity relationships. Compound 2 (3,6-dihydroxy-2-(3-hydroxyphenyl)-4H-chromen-4-one) was selected for pharmacokinetic studies. Encapsulation of compound 2 in PLGA nanoparticles or cyclodextrins resulted in lower in vitro toxicity when compared to the free compound. Combination studies with methotrexate revealed that compound 13 (3-hydroxy-6-methoxy-2-(4-methoxyphenyl)-4H-chromen-4-one) has the highest synergistic effect at concentration of 1.3 mu M 11.7-fold dose reduction index and no toxicity toward host cells. Our results provide the basis for further chemical modifications aimed at identifying novel antitrypanosomatidic agents showing higher potency toward PTR1 and increased metabolic stability.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available